中化新网讯 DNA因其海量存储潜力被视为下一代存储介质的有力竞争者，然而，高错误率的合成技术 是阻碍其实际应用的瓶颈。近日，天津大学应用数学中心与合成生物学国家重点实验室吴华明教授团队 在国际期刊《自然·通讯》上发表了题为《DNA StairLoop:实现DNA数据存储中高保真数据恢复和强大 的错误纠正》的研究成果，有望加速推动DNA数据存储从实验室走向产业化应用。 随着数据存储需求进入"泽字节时代"(1泽字节约等于1万亿GB)，DNA因其环境友好、稳定性高和存储 密度大等特点，被视为极具潜力的存储介质之一。然而，DNA数据存储的实际应用仍面临合成过程中 的技术瓶颈，尤其是在采用高扩展性、低成本的合成方法(如电化学合成)时，往往伴随较高的核苷酸错 误率与合成不均匀性问题，严重影响数据读写的可靠性。 为应对这一挑战，吴华明团队提出了一种名为StairLoop的DNA存储框架，旨在提升DNA存储系统在高 错误率合成环境下的数据恢复性能。该研究通过设计阶梯式交织结构与迭代式软判决解码机制，在不依 赖复杂多序列比对的前提下，实现了对插入、删除及替换等典型合成错误的有效校正。该方案还具备并 行解码能力，有助于提升大规模 ...

Financial Data and Key Metrics Changes - For the second quarter of fiscal 2025, the company reported record revenue of $92.8 million, an increase of 23% year over year and 4.6% sequentially [13][24] - Gross margin for the quarter was 49.6%, up from 41% in the same quarter of fiscal 2024, reflecting improved operational efficiency [13][29] - Adjusted EBITDA loss was approximately $14.8 million, an improvement of about $11.9 million compared to the second quarter of fiscal 2024 [30] Business Line Data and Key Metrics Changes - Revenue from Synbio increased to $36 million, a growth of 21% year over year [13][24] - NGS revenue grew to approximately $51.1 million, an increase of 25% year over year [16][25] - Biopharma services revenue was $5.7 million, reflecting a growth of 21% year over year [16][25] Market Data and Key Metrics Changes - Healthcare revenue rose to $52.8 million, up 29% year over year [26] - Industrial chemical revenue increased to $22.8 million, a 12% rise from the previous year [26] - Academic revenue was $16.5 million, up 20% year over year [27] Company Strategy and Development Direction - The company has spun out DNA Data Storage as an independent entity, Atlas Data Storage, to focus on commercialization and drive success [9][11] - The strategy emphasizes operational agility and customer engagement to maintain competitive positioning [18][19] - The company aims to achieve adjusted EBITDA breakeven by the end of fiscal 2026, with a focus on innovation and market share growth [34][35] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the future, citing strong order bookings exceeding $100 million in the last two quarters [38] - The company is prepared to navigate market volatility and leverage it as an opportunity for growth [36][38] - Management acknowledged challenges in the academic sector but remains confident in the value proposition of their products [72][74] Other Important Information - The company ended the quarter with cash, cash equivalents, and short-term investments of approximately $257.1 million [31] - The company expects gross margin improvements to exceed 50% in the latter half of the fiscal year [34] Q&A Session Summary Question: Impact of tariffs on guidance and demand from competitors - Management indicated that they have accounted for potential tariff impacts in their guidance and noted strong share gains despite macro challenges [40][42] Question: Effect of promotions on academic market growth - Management confirmed that the 20% growth in the academic market was partly due to promotional activities, which they plan to continue until the end of the fiscal year [47][50] Question: Guidance for NGS revenue from top customers - Management expects growth from both existing and new customers, with top customers growing at a rate similar to the overall NGS business [53][54] Question: Reinvestment of savings from the spin-off into R&D - Management confirmed that savings from the spin-off will be partially reinvested into higher priority R&D initiatives [56][61] Question: Academic market's importance and growth assumptions - Management highlighted a significant opportunity in the academic market, with expectations for continued growth despite budget constraints [83][84]